Tasimelteon

David Neubauer, Ahmed S. BaHammam, Seithikurppu R. Pandi-Perumal

Research output: Contribution to journalArticle

Abstract

The role of the melatonin in relation with circadian rhythms and the sleep/wake cycle is well established. It is thought to play a role in controlling the sleep–wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus. In normal subjects, the endogenous circadian period is a little over 24 h, but is entrained to the 24-h day through exposure to light. In the absence of light or light perception (totally blind), the synchronization is lost and the circadian rhythm follows the intrinsic non-24 h clock, resulting in a non-24 h sleep–wake disorder. Non-24 h sleep–wake disorder is characterized by a misalignment of the 24-h light/dark (LD) cycle and a non-entrained sleep/wake cycle propensity resulting in asymptomatic periods alternating with episodes of insomnia, excessive daytime sleepiness (EDS), or a combination of both. Tasimelteon (VEC-162) is an orally bioavailable melatonin receptor agonist of the melatonin MT1 and MT2 receptors recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24 h sleep–wake rhythm disorder.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalMilestones in Drug Therapy
Volume49
DOIs
StatePublished - 2015

Fingerprint

Circadian Rhythm
Light
Sleep
Melatonin MT1 Receptor
Melatonin MT2 Receptor
Melatonin Receptors
Physiological Phenomena
Suprachiasmatic Nucleus
Photoperiod
Sleep Initiation and Maintenance Disorders
Melatonin
United States Food and Drug Administration
Hypothalamus
tasimelteon
Therapeutics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Drug Discovery

Cite this

Neubauer, D., BaHammam, A. S., & Pandi-Perumal, S. R. (2015). Tasimelteon. Milestones in Drug Therapy, 49, 261-269. https://doi.org/10.1007/978-3-319-11514-6_13

Tasimelteon. / Neubauer, David; BaHammam, Ahmed S.; Pandi-Perumal, Seithikurppu R.

In: Milestones in Drug Therapy, Vol. 49, 2015, p. 261-269.

Research output: Contribution to journalArticle

Neubauer, D, BaHammam, AS & Pandi-Perumal, SR 2015, 'Tasimelteon', Milestones in Drug Therapy, vol. 49, pp. 261-269. https://doi.org/10.1007/978-3-319-11514-6_13
Neubauer, David ; BaHammam, Ahmed S. ; Pandi-Perumal, Seithikurppu R. / Tasimelteon. In: Milestones in Drug Therapy. 2015 ; Vol. 49. pp. 261-269.
@article{96cd197ff39e45c5977d8a3db7d7f9eb,
title = "Tasimelteon",
abstract = "The role of the melatonin in relation with circadian rhythms and the sleep/wake cycle is well established. It is thought to play a role in controlling the sleep–wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus. In normal subjects, the endogenous circadian period is a little over 24 h, but is entrained to the 24-h day through exposure to light. In the absence of light or light perception (totally blind), the synchronization is lost and the circadian rhythm follows the intrinsic non-24 h clock, resulting in a non-24 h sleep–wake disorder. Non-24 h sleep–wake disorder is characterized by a misalignment of the 24-h light/dark (LD) cycle and a non-entrained sleep/wake cycle propensity resulting in asymptomatic periods alternating with episodes of insomnia, excessive daytime sleepiness (EDS), or a combination of both. Tasimelteon (VEC-162) is an orally bioavailable melatonin receptor agonist of the melatonin MT1 and MT2 receptors recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24 h sleep–wake rhythm disorder.",
author = "David Neubauer and BaHammam, {Ahmed S.} and Pandi-Perumal, {Seithikurppu R.}",
year = "2015",
doi = "10.1007/978-3-319-11514-6_13",
language = "English (US)",
volume = "49",
pages = "261--269",
journal = "Milestones in Drug Therapy",
issn = "2296-6056",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Tasimelteon

AU - Neubauer, David

AU - BaHammam, Ahmed S.

AU - Pandi-Perumal, Seithikurppu R.

PY - 2015

Y1 - 2015

N2 - The role of the melatonin in relation with circadian rhythms and the sleep/wake cycle is well established. It is thought to play a role in controlling the sleep–wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus. In normal subjects, the endogenous circadian period is a little over 24 h, but is entrained to the 24-h day through exposure to light. In the absence of light or light perception (totally blind), the synchronization is lost and the circadian rhythm follows the intrinsic non-24 h clock, resulting in a non-24 h sleep–wake disorder. Non-24 h sleep–wake disorder is characterized by a misalignment of the 24-h light/dark (LD) cycle and a non-entrained sleep/wake cycle propensity resulting in asymptomatic periods alternating with episodes of insomnia, excessive daytime sleepiness (EDS), or a combination of both. Tasimelteon (VEC-162) is an orally bioavailable melatonin receptor agonist of the melatonin MT1 and MT2 receptors recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24 h sleep–wake rhythm disorder.

AB - The role of the melatonin in relation with circadian rhythms and the sleep/wake cycle is well established. It is thought to play a role in controlling the sleep–wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus. In normal subjects, the endogenous circadian period is a little over 24 h, but is entrained to the 24-h day through exposure to light. In the absence of light or light perception (totally blind), the synchronization is lost and the circadian rhythm follows the intrinsic non-24 h clock, resulting in a non-24 h sleep–wake disorder. Non-24 h sleep–wake disorder is characterized by a misalignment of the 24-h light/dark (LD) cycle and a non-entrained sleep/wake cycle propensity resulting in asymptomatic periods alternating with episodes of insomnia, excessive daytime sleepiness (EDS), or a combination of both. Tasimelteon (VEC-162) is an orally bioavailable melatonin receptor agonist of the melatonin MT1 and MT2 receptors recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24 h sleep–wake rhythm disorder.

UR - http://www.scopus.com/inward/record.url?scp=84921503447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921503447&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-11514-6_13

DO - 10.1007/978-3-319-11514-6_13

M3 - Article

VL - 49

SP - 261

EP - 269

JO - Milestones in Drug Therapy

JF - Milestones in Drug Therapy

SN - 2296-6056

ER -